Angela Cenci Nilsson
101 – 110 of 155
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Rodent models of treatment-induced motor complications in Parkinson's disease
(
- Contribution to journal › Article
- 2008
-
Mark
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
(
- Contribution to journal › Article
-
Mark
Two routes for L-dopa to be converted to dopamine
2008) 15th Annual Meeting of the American Society for Neural Therapy and Repair In Cell Transplantation 17(4). p.482-482(
- Contribution to journal › Published meeting abstract
-
Mark
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
(
- Contribution to journal › Article
- 2007
-
Mark
High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence
(
- Contribution to journal › Article
-
Mark
Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with DeltaFosB.
(
- Contribution to journal › Article
-
Mark
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors
(
- Contribution to journal › Article
-
Mark
Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model.
(
- Contribution to journal › Scientific review
-
Mark
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration.
(
- Contribution to journal › Article
-
Mark
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
(
- Contribution to journal › Article